We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly to Buy Boehringer's Vetmedica Pet Vaccines Unit
Read MoreHide Full Article
Eli Lilly and Company (LLY - Free Report) announced that its Elanco animal health business has agreed to acquire the U.S. pet vaccines unit – Vetmedica – and a Fort Dodge, IA-based manufacturing site from German drugmaker Boehringer Ingelheim for $885 million.
The acquisition of the Vetmedica portfolio of feline, canine and rabies vaccines, as well as several pipeline products, would be a strategic fit for Lilly’s animal health business that makes parasiticides, pain and dermatology medicines for food animals and companion animals.
The acquisition is expected to close early next year, subject to regulatory approvals as well as the closing of Boehringer Ingelheim's asset swap with Sanofi (SNY - Free Report) , which was signed in June this year.
Boehringer Ingelheim is swapping its consumer healthcare business with French drugmaker Sanofi’s Merial animal health business. The deal is expected to close by the end of 2016. (Read: Sanofi Inks Deal to Swap Business with Boehringer Ingelheim).
The acquisition is expected to be accretive to adjusted earnings in 2018.
We remind investors that Lilly bought the animal-health division of Novartis AG (NVS - Free Report) in early 2015.
Anika Therapeutics’ earnings estimates for 2016 and 2017 were up a respective 9.5% and 11.3% over the last 60 days. The company has recorded a positive earnings surprise in each of the last four quarters with an average beat of 42.19%. Its share price has jumped more than 25% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Eli Lilly to Buy Boehringer's Vetmedica Pet Vaccines Unit
Eli Lilly and Company (LLY - Free Report) announced that its Elanco animal health business has agreed to acquire the U.S. pet vaccines unit – Vetmedica – and a Fort Dodge, IA-based manufacturing site from German drugmaker Boehringer Ingelheim for $885 million.
The acquisition of the Vetmedica portfolio of feline, canine and rabies vaccines, as well as several pipeline products, would be a strategic fit for Lilly’s animal health business that makes parasiticides, pain and dermatology medicines for food animals and companion animals.
The acquisition is expected to close early next year, subject to regulatory approvals as well as the closing of Boehringer Ingelheim's asset swap with Sanofi (SNY - Free Report) , which was signed in June this year.
LILLY ELI & CO Price
LILLY ELI & CO Price | LILLY ELI & CO Quote
Boehringer Ingelheim is swapping its consumer healthcare business with French drugmaker Sanofi’s Merial animal health business. The deal is expected to close by the end of 2016. (Read: Sanofi Inks Deal to Swap Business with Boehringer Ingelheim).
The acquisition is expected to be accretive to adjusted earnings in 2018.
We remind investors that Lilly bought the animal-health division of Novartis AG (NVS - Free Report) in early 2015.
Lilly carries a Zacks Rank #3 (Hold). A stock worth considering in the healthcare sector is Anika Therapeutics Inc (ANIK - Free Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Anika Therapeutics’ earnings estimates for 2016 and 2017 were up a respective 9.5% and 11.3% over the last 60 days. The company has recorded a positive earnings surprise in each of the last four quarters with an average beat of 42.19%. Its share price has jumped more than 25% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>